CRISPR screen identifies SIRT5 as a metabolic vulnerability in AML but not in healthy hematopoietic cells. SIRT5 controls mitochondrial and glutamine metabolic pathways in AML. SIRT5 genetic or pharmacologic inhibition triggers apoptosis and delays leukemia progression, pointing to its potential as a therapeutic target for AML.

Histopathology features extracted by machine learning can identify MDS stage, prognosis, and genetic lesions, linking tissue morphology to underlying genetics and offering new tools for improved clinical evaluation for MDS.